艾普尼美德

最新新闻

• LifeSci Capital Maintains Apnimed(APMD.US) With Buy Rating, Maintains Target Price $50
  \u5e02\u573a\u8d44\u8baf · 2026/9/9
• Evercore Initiates Apnimed(APMD.US) With Buy Rating
  \u5e02\u573a\u8d44\u8baf · 2026/8/25
• LifeSci Capital Initiates Apnimed(APMD.US) With Buy Rating, Announces Target Price $50
  \u5e02\u573a\u8d44\u8baf · 2026/8/25
• BofA Securities Initiates Apnimed(APMD.US) With Buy Rating, Announces Target Price $41
  \u5e02\u573a\u8d44\u8baf · 2026/8/25
• A Quick Look at Today's Ratings for Apnimed(APMD.US), With a Forecast Between $41 to $60
  \u5e02\u573a\u8d44\u8baf · 2026/8/26

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。